Skip to main content
    P

    Palvella Therapeutics, Inc (PVLA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $144.60
    -7.88 (-5.17%)

    Market Cap: $2.23B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Palvella Therapeutics, Inc (PVLA) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Palvella Therapeutics (PVLA) to earn -$5.98 per share in the fiscal year ending Dec 31, 2026. Of 16 analysts, 16 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 16 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.

    RatingAnalystsShare
    Strong Buy00.0%
    Buy16100.0%
    Hold00.0%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    16

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a larger loss.

    Fiscal year ending Dec 31, 2026
    -$5.98
    EPS consensus
    Fiscal year ending Dec 31, 2027
    -$7.77
    EPS consensus, revenue $20.56M
    Next report
    Mar 29, 2027
    Estimated

    EPS range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$5.98-$6.40 to -$4.879N/AN/A15
    Dec 31, 2027-$7.77-$13.52 to -$3.5811$20.56M$6.50M to $53.61M14

    Quarterly Estimates

    The EPS consensus rises from -$2.15 for the quarter ending Dec 31, 2026 to -$2.07 for the quarter ending Mar 31, 2027.

    EPS range

    Quarter endingEPS consensusEPS rangeEPS analysts
    Dec 31, 2026-$2.15-$2.68 to -$1.7217
    Mar 31, 2027-$2.07-$2.40 to -$1.705

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 3 upward and 2 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202610
    Fiscal year ending Dec 31, 202721
    Quarter ending Mar 31, 202701

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$6.37.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$5.98-$6.39-$6.42-$6.37-$6.37N/A
    Fiscal year ending Dec 31, 2027-$7.77-$7.91-$7.50-$7.50-$7.50N/A
    Quarter ending Mar 31, 2027-$2.07-$2.18-$2.27-$2.27-$2.27N/A

    Frequently Asked Questions About PVLA

    What is the PVLA stock forecast?

    Consensus analyst estimates put Palvella Therapeutics's EPS at -$5.98 for the fiscal year ending Dec 31, 2026. The consensus rating from 16 analysts is Buy.

    How do analysts rate PVLA stock?

    Of 16 analysts covering Palvella Therapeutics, 0 rate it Strong Buy, 16 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from PVLA next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$5.98, with estimates from -$6.40 to -$4.87 from 9 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$7.77, with estimates from -$13.52 to -$3.58 from 11 analysts.

    What revenue do analysts expect from Palvella Therapeutics next year?

    For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $20.56M, with estimates from $6.50M to $53.61M.

    How many analysts cover PVLA?

    16 analysts rate Palvella Therapeutics stock, and 9 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.